|[July 17, 2014]
Precision Therapeutics Supports the Annual National Ovarian Cancer Coalition (NOCC) Run/Walk to Break the Silence
PITTSBURGH --(Business Wire)--
Precision Therapeutics is proud to be a national sponsor of the NOCC
2014 Run/Walk to Break the Silence on Ovarian Cancer. In addition to
sponsoring their local Pittsburgh Chapter event, Precision will be
present at NOCC run/walks taking place in Austin on August 10th,
Boston on September 7th, Dallas on September 21st,
and Providence on September 28th.
The goal of these events is to celebrate survivors, remember those lost
to ovarian cancer and raise awareness about the disease. As leaders in
personalizing treatment for ovarian cancer patients, Precision
understands the importance of these events and continues to encourage
employees to contribute by walking alongside ovarian cancer patients,
survivors and loved ones to help strengthen the bond that has been
created in the fight of this deadly disease.
As part of its national sponsorship, Precision will have an exhibit
space in each city and will provide every employee participating with a
"We are so honored to be working with the NOCC on a larger scale this
year. They continue to be a frontrunner in ovarian cancer education and
awareness, and we are delighted to be affiliated with such an amazing
group," said Sean McDonald, President and CEO of Precision Therapeutics.
"As a company we have always been dedicated to improving the outcomes of
cancer patients, and with this partnership we are one step closer to
achieving that goal." Precision specializes in developing products to
help guide physicians and patients with difficult clinical decisions
throughout the spectrum of cancer care.
The Pittsburgh NOCC Walk to Break the Silence will take place on Sunday,
September 14, 2014 at the North Park Boathouse. For more informatio on
the NOCC run/walks across the country, please visit www.ovarian.org.
About Ovarian Cancer:
More than 22,000 women in the United
States are newly-diagnosed with ovarian cancer each year. Approximately
80% of all women with ovarian
cancer have their disease recur, and 20-30% of recurrences occur
within 6 months of the end of first-line therapy. The majority of
patients with ovarian cancer (more than 70%), present with advanced
disease at initial diagnosis, and women with advanced ovarian cancer
tend to have multiple relapses and undergo several rounds of
chemotherapy. There have been modest gains in ovarian cancer statistics
in the last two decades, with only a small percentage of improvement in
overall survival rates for recurrent ovarian cancer.
About Precision Therapeutics:
Precision Therapeutics, Inc.,
a life-science company located in Pittsburgh, PA, is dedicated to
personalizing cancer care and improving patient outcomes. As leaders in
the science of individualizing cancer therapy, Precision develops novel
markers to help guide treatment decisions based on the biological
processes of each individual's cancer.
Precision's ChemoFx test is a proprietary drug response marker which
quantifies an individual gynecologic cancer patient's probable tumor
response to a range of standard chemotherapeutic options. ChemoFx has
been validated in previously conducted clinical studies, with data
demonstrating a 14-month
improvement in overall survival and 50% increase in progression-free
survival when recurrent ovarian cancer patients are treated with
'responsive' therapies as indicated by ChemoFx.
In addition to ChemoFx, Precision also offers BioSpeciFx®, a
portfolio of clinically relevant molecular tests that provide
information about drug response and patient prognosis. For more
information, visit: www.precisiontherapeutics.com or
[ Back To Unified Communications 's Homepage ]